Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and director of the Harvard Gene Therapy Initiative from 1996 to 2013. He also serves as executive vice chairman of the Board of Sana Biotechnology, Inc. From March 2017 to October 2018 Dr. Mulligan served as a portfolio manager at Icahn Capital LP. Prior to that, he was a professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and chief scientific officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was a founding partner of Sarissa Capital Management LP from 2013 to 2016. He was named a MacArthur Foundation Fellow in 1981.
Personal Details
Title: Dr
Surname: Mulligan
DoB: 01/01/2025
Age: 1 years
M/F: Male
Nationality: Canada
Country of Birth: Canada
Language: English
Qualification: Not available
Industry:
Qualifications & Experience
Industry Experience +5yrs:
Industry Qualification +5yrs?:
Finance experience +5yrs?:
Finance Qualification +5yrs:
Legal experience +5yrs?:
Delinquent director?:
Other Experiences?:
Collapsed company director?:
Other directorships (state)
(only entities turnover at least $5m p/a)
Company
Committee
Position
Date Appointed
Board
Vice Chairperson
Working history
Name
Other Executive
Biogen Inc Appointed Date: 01/06/2009 Date Resigned: 01/06/2023 Industry: Healthcare
Do you hold shares in the company for more than 0.10%? (directly or by representation):
Is your Director annual fee more than 5% of your total income from all sources?:
Are you more than 10 years as a director?:
Are you an executive chairperson?:
InsidEntity has assumed that responses to the Independent Questions are NO as the company has not populated the information. The result will present the Director as Independent.